| scholarly article | Q13442814 |
| P50 | author | Matthew Nayor | Q84973922 |
| Daniel Levy | Q88264418 | ||
| Ramachandran S. Vasan | Q30348351 | ||
| Jennifer E. Ho | Q37384761 | ||
| Martin G Larson | Q37390385 | ||
| P2093 | author name string | Na Wang | |
| P2860 | cites work | Galectin-3 and the development of heart failure after acute coronary syndrome: pilot experience from PROVE IT-TIMI 22 | Q82644905 |
| Predictors of insulin resistance in patients with obesity: a pilot study | Q85785995 | ||
| Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association | Q22241921 | ||
| Ranolazine: A Contemporary Review | Q26765421 | ||
| Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 | ||
| Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement | Q29619465 | ||
| Galectin 3 and incident atrial fibrillation in the community | Q33555143 | ||
| Abdominal subcutaneous and visceral adipose tissue and insulin resistance in the Framingham heart study | Q34551435 | ||
| Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice | Q34603941 | ||
| The age-specific quantitative effects of metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis | Q34917515 | ||
| Galectin-3, a biomarker linking oxidative stress and inflammation with the clinical outcomes of patients with atherothrombosis | Q35026202 | ||
| Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients - pilot study | Q36105680 | ||
| Addition of inflammatory biomarkers did not improve diabetes prediction in the community: the framingham heart study | Q36366235 | ||
| Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community | Q36439679 | ||
| Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community-based sample | Q36834958 | ||
| Elevated galectin-3 precedes the development of CKD | Q37119904 | ||
| Galectin-3: an emerging all-out player in metabolic disorders and their complications | Q38258947 | ||
| Free fatty acids and IL-6 induce adipocyte galectin-3 which is increased in white and brown adipose tissues of obese mice | Q38305642 | ||
| Adiponectin, leptin, interleukin-6 and HbA1c in the prediction of incident type 2 diabetes: A nested case-control study in Asian Indian men with impaired glucose tolerance | Q39001161 | ||
| Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets | Q40944709 | ||
| Some health benefits of physical activity. The Framingham Study | Q41722154 | ||
| Galectin-3 is a regulator of metaflammation in adipose tissue and pancreatic islets | Q42624178 | ||
| Galectin-3 activates PPARγ and supports white adipose tissue formation and high-fat diet-induced obesity. | Q42834230 | ||
| Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure | Q43163243 | ||
| Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes | Q43191933 | ||
| Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. | Q48024001 | ||
| The fibrosis marker galectin-3 and outcome in the general population | Q48821773 | ||
| New obesity indices and adipokines in normotensive patients and patients with hypertension: comparative pilot analysis. | Q51025890 | ||
| Adjusting for treatment effects in studies of quantitative traits: antihypertensive therapy and systolic blood pressure. | Q52991970 | ||
| Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. | Q53576992 | ||
| Galectin-3 predicts long-term cardiovascular death in high-risk patients with coronary artery disease. | Q53630691 | ||
| An investigation of coronary heart disease in families. The Framingham offspring study | Q59461737 | ||
| P433 | issue | 1 | |
| P577 | publication date | 2015-12-31 | |
| P1433 | published in | Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease | Q19880670 |
| P1476 | title | Circulating Galectin-3 Is Associated With Cardiometabolic Disease in the Community | |
| P478 | volume | 5 |
| Q40244362 | Alterations to adipose tissue morphology during inflammatory arthritis is indicative of vasculopathology in DBA/1 mice |
| Q47759940 | Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. |
| Q47329197 | Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). |
| Q55514878 | IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis. |
| Q90706189 | Sex-related differences in contemporary biomarkers for heart failure: a review |
Search more.